Gavocabtagene autoleucel

{
  "id": "MLC-T-ONC-013910",
  "term": "Gavocabtagene autoleucel",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous T lymphocytes that have been genetically engineered to express a single-domain antibody that recognizes human mesothelin, fused to the N-terminus of the CD3-epsilon T-cell receptor (TCR) subunit which, upon expression is incorporated into the endogenous TCR complex, with potential antineoplastic activity. Upon administration, gavocabtagene autoleucel specifically target and bind to mesothelin-expressing tumor cells. This leads to T-cell activation and T-cell mediated lysis of mesothelin-expressing tumor cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types. Compared to chimeric antigen receptor (CAR) T cells, TRuCs may be associated with less pro-inflammatory cytokine secretion and fewer adverse effects without compromising therapeutic efficacy.",
  "synonyms": [
    "autologous anti-mesothelin TRuC T cells TC-210",
    "autologous anti-mesothelin TRuC T cells",
    "autologous anti-mesothelin T-cell receptor fusion construct T cells TC-210",
    "Gavo-cel",
    "TC-210 T cells"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/gavocabtagene-autoleucel/"
}